City of Hope | Strategic Alliance Partners

March 24, 2022

Pamela S. Becker, MD, PhD, discusses the rationale for investigating uproleselan in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.

March 24, 2022

Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an investigation of nivolumab plus ipilimumab for patients with high tumor mutational burden, and more.

March 21, 2022

Afsaneh Barzi, MD, PhD, discusses the safety and efficacy of regorafenib in combination with pembrolizumab in patients with MSS colorectal cancer and describes potential next steps for further exploration of novel combinations in this population.

March 17, 2022

Haris Ali, MD, discusses updates in acute and chronic graft-vs-host-disease, current and emerging agents in myelofibrosis and polycythemia vera, and chronic lymphocytic leukemia management.

March 17, 2022

“I still have about 250 active patients with blood cancers, and every single one has my cell phone. I do everything in real time....That connection is very important and meaningful for me.”

February 25, 2022

Cancer Treatment Centers of America®, Phoenix, has achieved Magnet® recognition by the American Nurses Credentialing Center, positioning the cancer specialty hospital among a select group – just 8-10 percent of hospitals nationwide – to achieve this honor.

February 24, 2022

Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.

February 18, 2022

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

February 15, 2022

Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.

February 13, 2022

Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.

February 10, 2022

The organizations join forces to become one of the largest cancer research and treatment organizations in the country.

February 02, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

February 02, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss how and/or if any mentors they had during their careers helped them overcome gender-related challenges they experienced.

February 02, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, share insight on how the corporate culture has changed in oncology practices with regard to gender inequality.

February 02, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss some of the gender-related obstacles that they experienced throughout their careers as female oncologists.

February 01, 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss their early experiences as female oncologists and some of the gender-related challenges they faced during their careers.

January 27, 2022

Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and their advice to young women entering the field.

January 26, 2022

Afsaneh Barzi, MD, PhD, discusses the importance of developing novel therapies in metastatic colorectal cancer.

January 22, 2022

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

January 14, 2022

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.